On July 8, 2026, regulatory filings revealed that Ron-Bigger Shulamit, the Chief Operating Officer of Aktis Oncology, Inc. (NASDAQ: AKTS), executed a series of stock transactions resulting in the sale of approximately $1.39 million in common shares. The activity stemmed from the exercise of stock options that carried a vesting schedule initiated in September 2023.
The process began with the acquisition of 50,000 shares of Aktis Oncology common stock. These shares were obtained through option exercise at a cost of $3.66 per share, totaling $183,000. Immediately following this acquisition, Ron-Bigger disposed of all 50,000 newly acquired shares through open market sales. The total proceeds from these sales amounted to $1,387,557. The execution prices for these shares ranged from $26.52 to $28.76 per share.
The sales were structured in three distinct blocks. The first block consisted of 15,800 shares sold at a weighted average price of $27.1317, with individual prices varying between $26.5200 and $27.5100. The second block involved 30,000 shares sold at a weighted average price of $27.9379, with prices ranging from $27.5200 to $28.4700. The final block comprised 4,200 shares sold at a weighted average price of $28.7476, with individual prices between $28.7300 and $28.7600.
Following these transactions, Ron-Bigger holds no direct shares of common stock from this specific series of events. However, the executive retains derivative holdings that represent 217,888 shares. The sale occurs against a backdrop of recent market volatility for AKTS. The stock is currently trading at $28.42, marking an 11% decline over the past week. Despite this recent drop, the stock has posted a 27% gain over the last six months. Valuation metrics suggest the stock may be overvalued relative to its Fair Value, a classification that places it on InvestingPro's Most Overvalued list.
Beyond executive transactions, Aktis Oncology is advancing its clinical development pipeline. The company has initiated a Phase 1b clinical trial for AKY-2519, targeting patients with metastatic castration-resistant prostate cancer. This trial will be conducted across multiple prostate-specific radioligand therapy centers in the United States. The study design includes both PLUVICTO-naïve and PLUVICTO-experienced cohorts. Researchers will explore three different dose levels, with preliminary data anticipated to be available in 2027.
In parallel with clinical advancements, Aktis Oncology has strengthened its board leadership. The company appointed Glenn Gormley, MD, PhD, as an independent director. Dr. Gormley will also serve as co-chair of the newly established Science and Technology Committee. He brings more than 30 years of experience in the biopharmaceutical industry to the role. His previous positions include senior executive roles at Daiichi Sankyo Co., Ltd. His expertise in research and development is expected to influence the company's strategic direction.